# LITESPARK-001 (NCT02974738)

> A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

No report yet. It can be ordered.

- Drugs tested: belzutifan
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02974738
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions: Advanced Solid Tumors; Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; ccRCC; RCC, Clear Cell Adenocarcinoma; RCC; Kidney Cancer; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma, Metastatic; Renal Cell Carcinoma Recurrent; Renal Cell Carcinoma, Clear Cell Adenocarcinoma; Glioblastoma; Glioblastoma, Adult; GBM; Glioblastoma Multiforme
- Interventions: Belzutifan
- Enrollment: 120
- Primary outcome: maximum tolerated dose (MTD)

## Indexed commentary on LITESPARK-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=litespark-001-nct02974738